menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    CDSCO approves AstraZeneca’s anti-complement medicine

    EXPRESSPHARMA

    Samsung Bioepis, Teva Partner For Epysqli In US

    GLOBENEWSWIRE

    Novartis Fabhalta Improves Hemoglobin in PNH Patients from Anti-C5

    GLOBENEWSWIRE

    Samsung Bioepis`s Biologic Epysqli Receives Suppl Approval in US

    FDA

    Samsung Bioepis Presents Data On EPYSQLI At European Society

    GLOBENEWSWIRE

    Alexion`s Biologic Soliris (Eculizumab) Receives Suppl Approval in US

    FDA

    FDA Approves Samsung Bioepis` EPYSQLI As Biosimilar To Soliris

    GLOBENEWSWIRE

    Samsung Bioepis`s Biologic Epysqli (Eculizumab) Receives Approval in US

    FDA

    Samsung Bioepis Presents EPYSQLI Post-Hoc Analysis At EHA

    GLOBENEWSWIRE

    Samsung Bioepis Eculizumab Biosimilar EPYSQLI Post-Hoc Analysis At EHA

    GLOBENEWSWIRE

    US FDA approves Amgen`s biosimilar to AZ`s rare blood disorder treatment

    REUTERS

    FDA Approves First Interchangeable Biosimilar for Two Rare Diseases

    PR NEWSWIRE

    SEC recommends import, marketing permission for AstraZeneca`s rare disease drug

    PHARMABIZ

    Voydeya approved in the EU as add-on treatment to ravulizumab

    PRESS RELEASE

    Voydeya recommended for approval in the EU by CHMP

    PRESS RELEASE

    Alexion Pharma`s Biologic Soliris (eculizumab) Receives Approval in the U.S.

    FDA

    PIII trial data showed danicopan as add-on to ULTOMIRIS sustained improvements

    BUSINESSWIRE

    Soliris approved in Japan for paediatric patients with gMG

    PRESS RELEASE

    AstraZeneca secures paediatric gMG approval for Soliris in EU

    PRESS RELEASE

    Amgen`s Bekemv (eculizumab) Approved In Europe

    EMA

    Soliris recommended for approval in the EU by CHMP for children with gMG

    PRESS RELEASE

    AstraZeneca’s Soliris given EU CHMP recommendation for marketing authorisation

    PHARMATIMES

    Soliris approved for the treatment of refractory generalised myasthenia gravis

    PRESS RELEASE

    Samsung Bioepis`s Epysqli (Eculizumab) Receives Approval in the Europe

    EMA

    European Commission approves haematology biosimilar

    EUROPEAN PHARMACEUTICAL REVIEW

    AZ showcases advances across rare and malignant haematological conditions

    PHARMABIZ

    Amgen Technology`s Bekemv (Eculizumab) Receives Approval in the Europe

    EMA

    Samsung Bioepis Receives Positive CHMP Opinion for Eculizumab Biosimilar

    GLOBENEWSWIRE

    Health Canada grants approval for Sobi’s PNH therapy

    PHARMACEUTICAL-TECHNOLOGY

    Danicopan Add-On to ULTOMIRIS or SOLIRIS Met Primary Endpoint in ALPHA PIII

    BUSINESSWIRE

    Danicopan (ALXN2040) Add-On to ULTOMIRIS® or SOLIRIS® (eculizumab)

    BIOSPACE

    ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial

    BUSINESSWIRE

    Samsung Bioepis Presents New Phase 3 Study of SB12 (Eculizumab)

    GLOBENEWSWIRE

    AZ`s rare disease rising star Ultomiris snags 3rd FDA nod

    FIERCEPHARMA

    AstraZeneca`s Alexion, Arvinas nab space at new biotech tower

    FIERCEBIOTECH

    Argenx`s Vyvgart is already winning neurologist support

    FIERCEPHARMA

    Soliris needs a 97% to 98% discount in myasthenia gravis: ICER

    FIERCEPHARMA

    ICER Publishes Evidence Report on Treatments for Myasthenia Gravis

    FIRSTWORDPHARMA

    AstraZeneca lays out the red carpet for rare disease drug Alexion paid $855M for

    ENDPTS

    EU regulator backs AZ drug for rare blood disorder in children

    REUTERS

    Soliris needs substantial discount in myasthenia gravis: ICER

    FIERCEPHARMA

    BMS takes another late-stage loss for Opdivo-Yervoy combo in head & neck cancer

    ENDPTS

    Days after FDA clears C3 drug, Apellis spotlights ex-US PhIII win

    ENDPTS

    Apellis to Present Long-Term Pegcetacoplan Data at the EHA Congress

    GLOBENEWSWIRE

    NICE recommends Alexion’s PNH treatment Ultomiris

    NEUROEUROPE

    First approved C5 complement inhibitor recommended by NICE for NHS use

    PHARMAFILE

    Alexion`s Soliris (eculizumab) Receives Supplemental Approval in US

    FDA

    Apellis` Soliris rival gets a date at the FDA for a rare blood disorder

    ENDPTS

    PMDA Reviewing New Safety Risks for Soliris, Venclexta/Noxafil

    JIHO

    Novartis succeeds where Alexion failed, coming up with a win for a prized asset

    ENDPTS

    Novartis targets Alexion`s fiefdom after showing safe switch from Soliris

    FIERCE BIOTECH

    FDA Approves Roche’s ENSPRYNG for Neuromyelitis Optica Spectrum Disorder (NMOSD)

    PRESS RELEASE

    Alexion and Amgen Settle IPRs Over SOLIRIS (eculizumab)

    BIGMOLECULELAW

    DKSH extends long-term rare disease partnership in Hong Kong, Macau and Taiwan

    PRESS RELEASE

    New Pivotal Demonstrate Superiority of Apellis’ Pegcetacoplan to Eculizumab

    PRESS RELEASE

    Alexion Settles With Amgen Over Eculizumab Patents

    CENTERFORBIOSIMILAR

    For a post-Soliris world, Atlas-backed Q32 Bio outlines $46M next-gen

    ENDPTS

    Genentech posts long-term data on near-approval Soliris rival

    FIERCE BIOTECH

    As CEO bounces back from Covid-19, Apellis says FDA meeting clears path to file for an OK on Soliris rival

    ENDPTS

    Alexion will test rare disease drug Ultomiris in severe COVID-19

    PMLIVE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.